{"schema_version":"secwatch.filing_event.v1","accession":"0000064803-23-000003","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.768550+00:00","generated_at":"2026-06-20T18:22:09.318770+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CVS reaffirms FY2022 Adj. EPS guidance at high end; FY2023 Adj. EPS $8.70-$8.90","bullets":["Reaffirmed FY2022 Adj. EPS guidance $8.55-$8.65; expects high end on lower share count.","Expects to exceed FY2022 revenue guidance of $309B-$314B.","Reaffirmed FY2023 Adj. EPS guidance $8.70-$8.90, excluding Signify Health acquisition.","Repurchased ~15M shares in Q4 2022 at avg $99.99; entered $2B ASR effective Jan 3, 2023.","MA membership growth low-to-mid-single digit % in 2023; individual MA below expectations, exchange memberships >750k."],"urls":{"canonical":"https://secwatch.observer/filing/0000064803-23-000003","json":"https://secwatch.observer/filing/0000064803-23-000003.json","markdown":"https://secwatch.observer/filing/0000064803-23-000003.md","text":"https://secwatch.observer/filing/0000064803-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/0000064803-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/cvs-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:22:09.318770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51ca79ad23e8f78affcabd665a19fccc6b12fa83","claim":"CVS HEALTH Corp reported full-year 2023 results: EPS $8.70 to $8.90. Guidance reaffirmed.","evidence_excerpt":"The Company will also reaffirm its projected full-year 2023 Adjusted EPS guidance range of $8.70 to $8.90","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/0000064803-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"EPS","value":"$8.70 to $8.90"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d7c40f0a361a44085754da29eaa52a3debf8e438","claim":"CVS HEALTH Corp reported full-year 2022 results: EPS $8.55 to $8.65. Guidance reaffirmed.","evidence_excerpt":"the Company will disclose that it has reaffirmed its estimated full-year 2022 Adjusted earnings per share (\"EPS\") guidance range of $8.55 to $8.65","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/0000064803-23-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"EPS","value":"$8.55 to $8.65"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}